Free reads
8 reportsOpen to everyone, in full — the same as members get them.
Sector/Macro read09 Nov10 min read
The Nifty rose 2% and India's AI stocks fell 20%. Here's what actually happened on 6 November.
A US election started it, and memory chips carried it to India. The stock that fell hardest wasn't one that builds AI hardware. It was a laptop refurbisher, three days after its best quarter
Business update01 Oct12 min read
Sai Life Sciences: Building the Next Leg of Growth
FY26 showed what Sai Life Sciences looks like when revenue scales: 29% sales growth, EBITDA up 56% and margins from 25% to 30%. Now it is committing the largest capex programme in its history. This note is open to everyone, free to read in full.
Business update17 Sept4 min read
What you get as an F2F member
F2F (Forest to Flower) is my research membership on Indian markets: company deep dives, results analysis, sector and macro reads, audio notes, and answers to your own questions. Here is exactly what is inside, what it costs, and how to join.
Sector/Macro read04 Sept14 min read
India’s listed broking platforms after Q1 FY27: Groww vs Angel One
Billionbrains Garage Ventures (Groww) and Angel One both reported Q1 FY27 in mid-July. One grew revenue 66%, the other 25%. That gap is the story.
Business update04 Sept13 min read
Indo-MIM: strong numbers, but FY26 raises important questions
A newly listed company where the core is now the thing to track. Revenue grew 26%, but more than half the increment came from a loosely defined segment nobody has broken out.
Business update04 Sept12 min read
Electronics Mart India: strong Q1, but the real story starts now
The stock jumped after a blockbuster quarter. The bigger question is how to track this going forward — starting with the base it was measured against.
Business update17 Aug10 min read
Lenskart is screaming growth and we must not miss it
Lenskart is a growth story that if executed well, can create the next multibagger — but execution is the key.
Sector/Macro read12 Aug9 min read
Indian Pharma: Moving from volume to value
Unravelling the deeper macro theme developing in the Indian pharma space. India got very good at making the same medicine cheaper than anyone else — and that is exactly the skill the market has stopped paying for. What every large Indian pharma company is quietly rebuilding around instead.